Treatment of childhood post-irradiation sarcoma of bone in cancer survivors

G. Cefalo, A. Ferrari, J. D. Tesoro-Tess, M. C. Gianni, F. Fossati-Bellani, F. Lombardi, M. Massimino

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Patients and Methods. This is a retrospective review of five children with post-irradiation bone sarcoma (PIS). Age at PIg onset ranged between 10 and 17 years (median 11). They were treated with a chemotherapy regimen, similar to that in use for primary osteogenic sarcoma, consisting of vincristine and high-dose methotrexate alternated with cisplatinum and ifosfamide, given for 12 months. Results. In all children chemotherapy induced a complete clinical remission. Four of them were alive in continuous complete remission at 1, 2, 4, and 12 years from the diagnosis of bone sarcoma. One girl recurred 3 years from PIS diagnosis and was salvaged by repeating the same chemotherapy program: she remained alive in second complete remission 8 years from relapse. Conclusions. In spite of an intensive treatment previously given for the primary tumor, this drug schedule proved to be feasible and short-term side effects were manageable. Chemotherapy alone, using an intensive regimen effective for primary osteogenic sarcoma, may be an adequate therapy for childhood post-irradiation sarcoma.

Original languageEnglish
Pages (from-to)568-572
Number of pages5
JournalMedical and Pediatric Oncology
Volume29
Issue number6
DOIs
Publication statusPublished - 1997

Fingerprint

Bone Neoplasms
Sarcoma
Survivors
Drug Therapy
Osteosarcoma
Bone and Bones
Ifosfamide
Vincristine
Therapeutics
Age of Onset
Methotrexate
Appointments and Schedules
Recurrence
Pharmaceutical Preparations
Neoplasms

Keywords

  • Chemotherapy
  • Childhood cancer survivors
  • Post-irradiation bone sarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pediatrics, Perinatology, and Child Health

Cite this

Treatment of childhood post-irradiation sarcoma of bone in cancer survivors. / Cefalo, G.; Ferrari, A.; Tesoro-Tess, J. D.; Gianni, M. C.; Fossati-Bellani, F.; Lombardi, F.; Massimino, M.

In: Medical and Pediatric Oncology, Vol. 29, No. 6, 1997, p. 568-572.

Research output: Contribution to journalArticle

Cefalo, G. ; Ferrari, A. ; Tesoro-Tess, J. D. ; Gianni, M. C. ; Fossati-Bellani, F. ; Lombardi, F. ; Massimino, M. / Treatment of childhood post-irradiation sarcoma of bone in cancer survivors. In: Medical and Pediatric Oncology. 1997 ; Vol. 29, No. 6. pp. 568-572.
@article{c7c34707af3d407a8ed003c5b57b369e,
title = "Treatment of childhood post-irradiation sarcoma of bone in cancer survivors",
abstract = "Patients and Methods. This is a retrospective review of five children with post-irradiation bone sarcoma (PIS). Age at PIg onset ranged between 10 and 17 years (median 11). They were treated with a chemotherapy regimen, similar to that in use for primary osteogenic sarcoma, consisting of vincristine and high-dose methotrexate alternated with cisplatinum and ifosfamide, given for 12 months. Results. In all children chemotherapy induced a complete clinical remission. Four of them were alive in continuous complete remission at 1, 2, 4, and 12 years from the diagnosis of bone sarcoma. One girl recurred 3 years from PIS diagnosis and was salvaged by repeating the same chemotherapy program: she remained alive in second complete remission 8 years from relapse. Conclusions. In spite of an intensive treatment previously given for the primary tumor, this drug schedule proved to be feasible and short-term side effects were manageable. Chemotherapy alone, using an intensive regimen effective for primary osteogenic sarcoma, may be an adequate therapy for childhood post-irradiation sarcoma.",
keywords = "Chemotherapy, Childhood cancer survivors, Post-irradiation bone sarcoma",
author = "G. Cefalo and A. Ferrari and Tesoro-Tess, {J. D.} and Gianni, {M. C.} and F. Fossati-Bellani and F. Lombardi and M. Massimino",
year = "1997",
doi = "10.1002/(SICI)1096-911X(199712)29:6<568::AID-MPO9>3.0.CO;2-I",
language = "English",
volume = "29",
pages = "568--572",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Treatment of childhood post-irradiation sarcoma of bone in cancer survivors

AU - Cefalo, G.

AU - Ferrari, A.

AU - Tesoro-Tess, J. D.

AU - Gianni, M. C.

AU - Fossati-Bellani, F.

AU - Lombardi, F.

AU - Massimino, M.

PY - 1997

Y1 - 1997

N2 - Patients and Methods. This is a retrospective review of five children with post-irradiation bone sarcoma (PIS). Age at PIg onset ranged between 10 and 17 years (median 11). They were treated with a chemotherapy regimen, similar to that in use for primary osteogenic sarcoma, consisting of vincristine and high-dose methotrexate alternated with cisplatinum and ifosfamide, given for 12 months. Results. In all children chemotherapy induced a complete clinical remission. Four of them were alive in continuous complete remission at 1, 2, 4, and 12 years from the diagnosis of bone sarcoma. One girl recurred 3 years from PIS diagnosis and was salvaged by repeating the same chemotherapy program: she remained alive in second complete remission 8 years from relapse. Conclusions. In spite of an intensive treatment previously given for the primary tumor, this drug schedule proved to be feasible and short-term side effects were manageable. Chemotherapy alone, using an intensive regimen effective for primary osteogenic sarcoma, may be an adequate therapy for childhood post-irradiation sarcoma.

AB - Patients and Methods. This is a retrospective review of five children with post-irradiation bone sarcoma (PIS). Age at PIg onset ranged between 10 and 17 years (median 11). They were treated with a chemotherapy regimen, similar to that in use for primary osteogenic sarcoma, consisting of vincristine and high-dose methotrexate alternated with cisplatinum and ifosfamide, given for 12 months. Results. In all children chemotherapy induced a complete clinical remission. Four of them were alive in continuous complete remission at 1, 2, 4, and 12 years from the diagnosis of bone sarcoma. One girl recurred 3 years from PIS diagnosis and was salvaged by repeating the same chemotherapy program: she remained alive in second complete remission 8 years from relapse. Conclusions. In spite of an intensive treatment previously given for the primary tumor, this drug schedule proved to be feasible and short-term side effects were manageable. Chemotherapy alone, using an intensive regimen effective for primary osteogenic sarcoma, may be an adequate therapy for childhood post-irradiation sarcoma.

KW - Chemotherapy

KW - Childhood cancer survivors

KW - Post-irradiation bone sarcoma

UR - http://www.scopus.com/inward/record.url?scp=0030882851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030882851&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-911X(199712)29:6<568::AID-MPO9>3.0.CO;2-I

DO - 10.1002/(SICI)1096-911X(199712)29:6<568::AID-MPO9>3.0.CO;2-I

M3 - Article

C2 - 9324346

AN - SCOPUS:0030882851

VL - 29

SP - 568

EP - 572

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 6

ER -